Sal Patel, JD: Ongoing BPCIA Litigations

Sal Patel, JD, partner at Schiff Hardin, LLP, explains why he is watching litigations concerning rheumatoid arthritis drugs closely.


Are there some ongoing Biologics Price Competition and Innovation Act (BPCIA) litigations that you’re keeping your eye on?

Well, I am watching very closely the litigations involving biologics that are related to rheumatoid arthritis. There are a number of them going on, and I think that what happens in those cases and how those companies are going to be able to penetrate the market is going to determine whether other companies—smaller companies that have developed biosimilars in places like India, where they have developed and launched them—whether they will get into the biosimilar game in the United States.